USDA approves three new VaxLiant adjuvants for poultry vaccines

LINCOLN, Neb., June 30, 2015 — The U.S. Department of Agriculture (USDA) has approved the safety of the first ENABL ready-to-use adjuvants for vaccines used in chickens. The approval includes a 21-day withdrawal period when ENABL is used in vaccines administered subcutaneously (SQ) to improve immunity against disease.

"Each day is critical when developing and using vaccines to protect poultry health," says Steve Schram, VaxLiant co-founder. "The low, 21-day withdrawal requirement — which is the shortest allowed by USDA for food-animal vaccines — is especially helpful when developing vaccines for practical use. Having access to novel adjuvants that are safety-approved means manufacturers can reference existing withdrawal studies that already have met stringent standards, potentially reducing the timeline for developing new vaccines."

Approval of these three adjuvants brings the total of USDA-approved ENABL formulations to 13 — including five for use in cattle vaccines and five for swine vaccines. This means researchers now have more options for developing cutting-edge vaccines to help improve the immune response in chickens, pigs and cattle.

"Access to a variety of ready-to-use ENABL formulations allows companies to select the one that will bring out the best in their specific vaccines," says Timothy Miller, Ph.D., VaxLiant co-founder. "Next-generation adjuvants, like ENABL, aid in the development of new vaccines that will allow us to help improve the immune response to diseases more effectively than ever before."

For more information about VaxLiant, and its antigen-delivery systems and services, call 800-533-8617, email [email protected] or visit VaxLiant.com.

ENABL is a novel, ready-to-use adjuvant from VaxLiant that can be added to vaccines to help improve the resulting immune response in cattle, poultry and swine. USDA already has approved the safety of 13 ENABL formulations for cattle, swine and poultry vaccines with a 21-day withdrawal period, the shortest allowed for food-animal vaccines.

VaxLiant provides innovative antigen-delivery systems and technical support that give companies the flexibility they need to develop and commercialize safe, effective vaccines. VaxLiant is a joint venture between two established companies: Benchmark Biolabs, Lincoln, Nebraska, which has provided streamlined research-to-commercialization services since 1996, and AgriLabs, St. Joseph, Missouri, a leader in marketing vaccines, nutritionals and other animal-health products for more than 30 years.
###

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…